COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN SWEDEN
Author(s)
Baker TM1, Paly VF1, Thybo S2, Hultberg M3, Minacori R4, Kotapati S2, Sabater J2
1ICON Health Economics & Epidemiology, New York City, NY, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3PAREXEL International, Stockholm, Sweden, 4PAREXEL International, London, UK
OBJECTIVES:
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PCN126
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Oncology
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now